奥扎格雷与依达拉奉联合治疗急性脑梗死的疗效观察

The clinical effect observation of combination therapy with edaravone and ozagrel for acute cerebral infarction

目的探讨奥扎格雷与依达拉奉联合治疗急性脑梗死的疗效。方法238例急性脑梗死患者随机分为三组:丹奥(奥扎格雷)组、必存(依达拉奉)组、丹奥与必存联合治疗组。三组在梗死分型、梗死面积、入院时神经功能缺损积分及其他治疗方面均具有可比性。分别于入院当日、第7天、第14天、第21天评定美国国立卫生院卒中患者神经机能缺损评分量表(NIHSS)及日常生活活动能力量表(ADL),比较疗效。结果2周后丹奥与必存联合治疗组较单用丹奥、必存组患者的神经功能缺损程度明显降低,p<0.05;日常生活指数行为能力明显提高,P<0.05。结论奥扎格雷与依达拉奉联合治疗急性脑梗死效果明显好于该两药的单药治疗。

Objective To observate and discuss the clinical effect of combination therapy with edaravone and ozagrel for acute cerebral infarction, as to find a better therapy to treat apoplectics. Methods The case-control trail was carried out. 283 inpatients of acute cerebral infarction were randomly divided into three groups ,including edaravone group, ozagrel group and combination therapy group. The index included National Institutes of Health Stroke （NIHSS） and Barthel exponent of different time （day 7, dayl4, day21）. Results NIHSS was significantly decreased in the combination therapy group compared with single therpy groups and Barthel exponent was increased after 14 day the patients inpatiented. Conclusions The combination therapy was evidently better than the single treatments either edaravone or ozagrel, which is worthwhile to spread around.